A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Public ClinicalTrials.gov record NCT04519645. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Randomized, Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Study identification
- NCT ID
- NCT04519645
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 29 participants
Conditions and interventions
Interventions
- Lacosamide intravenous Drug
- Lacosamide oral Drug
- Active Comparator Other
Drug · Other
Eligibility (public fields only)
- Age range
- Up to 28 Days
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2021
- Primary completion
- Aug 5, 2024
- Completion
- Oct 30, 2024
- Last update posted
- Oct 2, 2025
2021 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sp0968 101 | La Jolla | California | 92037 | — |
| Sp0968 108 | Long Beach | California | 90806 | — |
| Sp0968 116 | Los Angeles | California | 90095 | — |
| Sp0968 190 | San Diego | California | 92123 | — |
| Sp0968 118 | Aurora | Colorado | 80045 | — |
| Sp0968 104 | Jacksonville | Florida | 32207 | — |
| Sp0968 107 | Miami | Florida | 33155 | — |
| Sp0968 112 | Iowa City | Iowa | 52242 | — |
| Sp0968 125 | Valhalla | New York | 10595 | — |
| Sp0968 117 | Portland | Oregon | 97239 | — |
| Sp0968 109 | Austin | Texas | 78723 | — |
| Sp0968 192 | Salt Lake City | Utah | 84113 | — |
| Sp0968 105 | Salt Lake City | Utah | 84132 | — |
| Sp0968 102 | Charlottesville | Virginia | 22903 | — |
| Sp0968 122 | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04519645, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04519645 live on ClinicalTrials.gov.